NUBACT XL
NUBACT XL
An unique combination of well studied strains of streptococcus fecalis, Clostridium Butyricum, Bacillus Mesentericus and Bacillus Coagulans is effective in the management of Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic Steato Hepatosis (NASH), Inflammatory Bowel Disease – Crohn’s Disease / Ulcerative Colitis, Clostridium difficle associated Diarrhea – co-prescribed with Proton Pump Inhibitors (PPIs).
NUBACT XL
An unique combination of well studied strains of streptococcus fecalis, Clostridium Butyricum, Bacillus Mesentericus and Bacillus Coagulans is effective in the management of Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic Steato Hepatosis (NASH), Inflammatory Bowel Disease – Crohn’s Disease / Ulcerative Colitis, Clostridium difficle associated Diarrhea – co-prescribed with Proton Pump Inhibitors (PPIs).
.
Therapeutic Uses:
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Non-alcoholic Steato Hepatosis (NASH)
- Inflammatory Bowel Disease – Crohn’s Disease / Ulcerative Colitis
- Clostridium difficle associated Diarrhea – co-prescribed with Proton Pump Inhibitors (PPIs)
Ingredients:
- Each capsule contains:
- Streptococcus fecalis not less than 60 million CFU
- Clostridium butyricum not less than 4 million CFU
- Bacillus mesentericus not less than 2 million CFU
- Bacillus coagulans not less than 100 million CFU
Each 0.5 g sachet contains:
- Streptococcus fecalis not less than 30 million CFU
- Clostridium butyricum not less than 2 million CFU
- Bacillus mesentericus not less than 1 million CFU
- Bacillus coagulans not less than 50 million CFU
Visited 146 times, 1 visit(s) today
Since 1969, when we entered into a Joint Venture with Sankyo (now Daiichi-Sankyo) to make gonadotropins to export to Japan, we’ve been at the forefront of biological hormones, and today we have the necessary technological foundation to do path breaking work.